Management of Refractory OAB in the Non-Neurogenic Patient

Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999;83:583–90. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40. Goldman HB, Wyndaele JJ, Kaplan SA, Wang JT, Ntanios F. Defining response and non-response to treatment in patients with overactive bladder: a systematic review. Curr Med Res Opin. 2014;30:509–26. A very good review on how success/failure is defined in the literature regarding the response to various remedies of OAB. The article shows that the literature is lacking a clear, standardized form of treatment response. Robinson D, Giarenis I, Cardozo L. The medical management of refractory Overactive Bladder. Maturitas. 2013;74:386–90. This manuscript is an overview for pharmacotherapy of OAB. It can also serve as baseline knowledge for the reader on the subject of evaluation. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65:79–95. Jeong SJ, Lee SC, Jeong CW, Hong SK, Byun SS, Lee SE. Clinical and urodynamic differences among women with overactive bladder according to the presence of detrusor overactivity. Int Urogynecol J. 2013;24:255–61. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. J Urol. 2012;188:2455–63. An updated and comprehensive guideline, noteworthy for any urologist. Yamauchi H, Akino H, Ito H, Aoki Y, Nomura T, Yokoyama O. Urinary prostaglandin E2 was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. Urology. 2010;76:1267. E 13–9. Seth JH, Sahai A, Khan MS, van der Aa F, de Ridder D, Panicker JN, et al. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int. 2013;111:372–80. Cho KJ, Kim HS, Koh JS, Kim JC. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics. Int Urogynecol J. 2013;24:325–30. Rubio-Diaz DE, Pozza ME, Dimitrakov J, et al. A candidate serum biomarker for bladder pain syndrome/interstitial cystitis. Analyst. 2009;134:1133–7. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. 4th ed. Paris: Health Publication Ltd; 2009. p. 631–700. Editions 21. Armstrong EP, Malone DC, Bui CN. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. J Med Econ. 2012;15(Supp 1):35–44. Bolduc S, Moore K, Lebel S, Lamontagne P, Hamel M. Double anticholinergic therapy for refractory overactive bladder. J Urol. 2009;182:2033–9. Natalin R, Oliveira Reis L, Alpendre C, Ikari L, Prudente A, D’Ancona C. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol. 2010;28:79–85. Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database of Syst Rev. 2012;Issue 12. Art. No.: CD003193. Important review outlines different comparisons of antimuscarnincs vs. anything else. Ansari MS, Bharti A, Kumar R, Ranjan P, Srivastava S, Kapoor R. Gabapentin: a novel drug as add-on therapy in cases of refractory overactive bladder in children. J Pediatr Urol. 2013;9:17–22. Schmidt RA, Tanagho EA. Feasibility of controlled micturition through electric stimulation. Urol Int. 1979;34:199–230. Thüroff JW, Bazeed MA, Schmidt RA, Wiggin DM, Tanagho EA. Functional pattern of sacral root stimulation in dogs. I Micturition. J Urol. 1982;127:1031–3. Thüroff JW, Bazeed MA, Schmidt RA, Wiggin DM, Tanagho EA. Functional pattern of sacral root stimulation in dogs. II. Urethral closure. J Urol. 1982;127:1034–8. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol. 1988;140:1331–9. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol. 1999;162:352–7. Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2014. doi:10.1002/nau.22544. Govier FE, Litwiller S, Nitti V, Kreder Jr KJ, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165:1193–8. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31:1206–16. Ammi M, Chautard D, Brassart E, Culty T, Azzouzi A, Bigot P. Transcutaneous posterior tibial nerve stimulation: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder. Int Urogynecol J. 2014. doi:10.1007/s00192-014-2359-0. Peters K, Carrico D, Burks F. Validation of a sham for Percutaneous Tibial Nerve Stimulation (PTNS). Neurourol Urodyn. 2009;28:58–61. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43. Tellenbach M, Schneider M, Mordasini L, Thalmann GN, Kessler TM. Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome? World J Urol. 2013;31:1205–10. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177–85. Okamura K, Nojiri Y, Ameda K, Namima T, Suzuki M, Inoue K, et al. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes. Int J Urol. 2011;18:483–7. Makovey I, Davis T, Guralnick ML, O’Connor RC. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability. Neurourol Urodyn. 2011;30:1538–40. Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784–95. Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type a injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61:834–9. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416–22. Wein A. Diagnosis and treatment of the overactive bladder. Urology. 2003;62(Supple. 5B):20–7. Reyblat P, Ginsberg DA. Augmentation enterocystoplasty in overactive bladder: is there still a role? Curr Urol Rep. 2010;11:432–9. Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int. 2001;88:511–25